Using the AACR Health Disparities Report to Drive Change in Cancer Care

Commentary
Video

The AACR Health Disparities Report highlights the changes needed to achieve health equity for patients with cancer.

The American Association for Cancer Research (AACR) Health Disparities Report is a powerful tool that can help educate those in the oncology community on health equity issues among patients with cancer, according to Robert A. Winn, MD.

Winn described his experiences with organizing the AACR Health Disparities Reports since the publication of the first in 2020. He stated that he was “happy” to be involved in this effort to help spread awareness of cancer disparities.

Winn, director and Lipman Chair in Oncology at Virginia Commonwealth University (VCU) Massey Comprehensive Cancer Center, senior associate for Cancer Innovation, and professor of Pulmonary Disease and Critical Cancer Medicine at VCU School of Medicine, also touched on how working with other professional bodies such as the American Cancer of Clinical Oncology (ASCO) may achieve the goal of educating others on heath disparity issues in oncology.

Transcript:

The education part of this is exciting for us. I hope that the AACR Health Disparities Report is just 1 tool to not only get my colleagues but to get people within the community and get those people who are in charge of our resources a little bit more up-to-speed and aware. This report has, on its own, been substantiated. I was part of the first one in 2020, and part of the second one in 2022. I’m happy to be part of [the 2023] one as well and leading the charge of the 2024 report. That’s one element that we hope will be able to help educate people and bring awareness. The other one is just [the] good old-fashioned [strategy of] having our professional bodies, whether they’re AACR, AACI [Association of American Cancer Institutes], American Cancer Society, or ASCO [American Society of Clinical Oncology] all working on one accord, and that is to bring to the attention that cancer is not like it used to be in the 1950s. It is not necessarily a death sentence if you can get to the right place and get the right care at the right time.

Reference

Experts forecast 2024, part 2: achieving cancer health equity. News release. AACR. January 12, 2024. Accessed February 16, 2024. https://shorturl.at/cMQR8

Recent Videos
Beyond DNA-centric diagnostics, protein-based methods may play a role in accurately matching patients with the most effective therapies.
Biochemical markers and advanced imaging modalities play a critical role in monitoring patients undergoing RLT therapy for metastatic prostate cancer.
Less lymphocyte depletion with twice-daily radiotherapy warrants further assessment to optimize the synergistic effect of radiotherapy and immunotherapy.
David Rimm, MD, PhD, discussed how AI tools may help automate routine tasks for pathologists and predict genomic alterations from images.
Data support the use of radioligand therapy in combination with androgen receptor pathway inhibitors to optimize prostate cancer outcomes.
Twice-daily thoracic radiotherapy appeared to confer less leukocyte and lymphocyte depletion compared with once-daily radiation in LS-SCLC.
Related Content
Twice-daily radiotherapy prolongs survival vs once-daily radiation among those with LS-SCLC, even with the incorporation of immunotherapy.

Unraveling The Benefits of Twice-Daily Chemoradiotherapy in LS-SCLC

Russ Conroy
October 3rd 2025
Article

Twice-daily radiotherapy prolongs survival vs once-daily radiation among those with LS-SCLC, even with the incorporation of immunotherapy.

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

Diving Into the Practical Applications of ctDNA in Oncology Care

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Arnab Basu, MBBS, MPH, FACP
September 25th 2025
Podcast

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

Acknowledging Mortality and Death in Cancer Care

Acknowledging Mortality and Death in Cancer Care

Ariana Pelosci
September 29th 2025
Article

In the oncology setting, having discussions about mortality and death may be daunting for patients, but is vital and inevitable.

How to Discuss Death: A Conversation of Mortality in Cancer Care

How to Discuss Death: A Conversation of Mortality in Cancer Care

Daniel C. McFarland, DO;William Breitbart, MD
September 22nd 2025
Podcast

Daniel C. McFarland, DO; and guest William S. Breitbart, MD, discuss the critical role of meaning-centered therapy in addressing the psychosocial needs of patients with cancer.

Managing AEs with Gemcitabine Intravesical System in NMIBC

Managing AEs with Gemcitabine Intravesical System in NMIBC

Gary Steinberg, MD
September 20th 2025
Article

Gary Steinberg, MD, compared the AE profile of the gemcitabine intravesical system for BCG-unresponsive NMIBC with other intravesical therapies.

Data from the phase 3 3475A-D77 trial support the FDA approval of subcutaneous pembrolizumab across different pediatric and adult solid tumor indications.

FDA Approves SC Pembrolizumab Formulation in Solid Tumors

Tim Cortese
September 19th 2025
Article

Data from the phase 3 3475A-D77 trial support the FDA approval of subcutaneous pembrolizumab across different pediatric and adult solid tumor indications.